- Policy
- Additional Paxlovid for 10,000 people will be introduced
- by Kang, Shin-Kook Jan 20, 2022 05:54am
- Prime Minister Kim Bu-gyeom announced that he would introduce an additional 10,000 servings at the end of this month as patients' condition improved after taking the COVID-19 treatment. Prime Minister Kim posted a message on his SNS on the 17th and said, "The prescription and administration of COVID-19 treatment began last week." He said,
- Policy
- Bill for Rotarix·RotaTeq to be covered by NIP
- by Lee, Jeong-Hwan Jan 19, 2022 06:06am
- A bill to promote the health of infants and young children while reducing consumer burden by including rotavirus vaccines in the National Immunization Program (NIP) is being promoted. If passed, the bill will turn GSK’s Rotarix and MSD’s RotaTeq that are already being used in Korea into free national vaccinations. Since the WHO recomme
- Policy
- The benefit standard for Braftovi & Lorviqua was set
- by Lee, Hye-Kyung Jan 19, 2022 06:06am
- At the first Severe (Cancer) Disease Review Committee held this year, the benefit standards for Braftovi, a direct bowel cancer treatment of Ono Pharmaceutical Korea, and Pfizer's Lorviqua, were set. The HIRA (Director Kim Sun-min) today (12th) released the "Result of Review on benefit Standards for Drugs for Cancer Patients" reviewed by t
- Policy
- Daewoong tx are being developed for skin side effects
- by Lee, Tak-Sun Jan 18, 2022 06:06am
- Daewoong Pharmaceutical has started to develop a treatment for skin side effects caused by anticancer drugs. This treatment is known as a stem cell-based drug. The MFDS approved the phase 2 clinical trial plan for DWP708 submitted by Daewoong Pharmaceutical on the 17th. This clinical trial is conducted to explore the efficacy of DwP1708 an
- Policy
- Discord in system hinder coverage of rare disease drugs
- by Lee, Jeong-Hwan Jan 18, 2022 06:06am
- A suggestion has been raised that it is irrational for a drug that received an orphan drug designation to be ineligible for insurance benefits that were set for rare disease treatments to improve patient accessibility because its disease was not designated as a rare disease or set for special exemption of calculation. In other words, the trea
- Policy
- The gov will push for a refund on losses from suspension
- by Kim, Jung-Ju Jan 18, 2022 06:05am
- The government will push for a revision of the law that will put a brake on the suspension of execution filed by pharmaceutical companies in drug price lawsuits. If companies fight against the government over drug prices and finally win the case, the insurer will refund the drug cost equivalent to the loss so far. This is a revision of the legal
- Policy
- A plan to expand patient access to Kymriah should be passed
- by Kim, Jung-Ju Jan 17, 2022 05:51am
- While the agenda for the health insurance registration of the ultra-high-priced innovative drug Kymriah and the expansion of immuno-cancer drug Keytruda benefits have been in full swing since the afternoon of today (13th), patient groups gathered in front of the Kukje Electronic Center's Smart Work Center. Patient maximum co-payment of
- Policy
- The ultra-high-priced new drug Kymriah passed the Committee
- by Lee, Hye-Kyung Jan 14, 2022 05:50am
- Kymriah(Tisagenlecleucel) of Novartis Korea, dubbed an ultra-high-priced "one-shot treatment" with a cost of 500 million won per dose, passed the committee. The HIRA (Director Kim Sun-min) held the first Drug Reimbursement Evaluation Committee in 2021 on the afternoon of the 13th and conducted a review on the appropriateness of medical care bene
- Policy
- MOHW·MOTIE accelerates Global COVID-19 Vaccine Hub project
- by Kim, Jung-Ju Jan 14, 2022 05:50am
- The Ministry of Health and Welfare (MOHW) and the Ministry of Trade, Industry, and Energy (MOTIE) joined forces to come up with a plan to accelerate the government’s goal of Korea becoming a ‘Global Vaccine Hub’ that was set last year. On the morning of the 13th, Minister of Health and Welfare Kwon Deok-Chul and First Vice Minister of T
- Policy
- COVID-19 vaccine by NovaVax is approved in Korea
- by Lee, Tak-Sun Jan 14, 2022 05:50am
- COVID-19 vaccine by NovaVax was approved for domestic items on the 12th. At the final inspection committee held on the same day, experts judged that the Novavax vaccine had a sufficient effect on preventing COVID-19. The MFDS announced on the 12th that SK Bioscience has decided to approve the product on the condition that it submits a fina
